Brett Gilbert, DO
Infectious Disease · Wynnewood, PANPI 1275599532
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $308,782 of the $351,687 with a category attached, or 87.8%. Pfizer accounts for 89.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $131,849 and has fallen 51.4% since, to $64,100 in 2025. Among infectious disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 363 payments — averaging $968.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$314K
- Merck$24K
- AbbVie$13K
- Gilead$32
- Viiv Healthcare Company$29
- Johnson & Johnson$28
- plus $47 from 2 others
What the payments were for
- Consulting fees$5,7052%
- Speaking & faculty fees$308,78288%
- Travel & lodging$30,2089%
- Food & beverage$6,9032%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 296 | $314,116 |
| Merck | 34 | $24,112 |
| AbbVie(2 entities) | 26 | $13,323 |
| Gilead | 2 | $32 |
| Viiv Healthcare Company | 2 | $29 |
| Johnson & Johnson | 1 | $28 |
| Genentech USA, Inc. | 1 | $25 |
| Insmed, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$351,687 in reported general payments places this provider in the 95th percentile of 457 infectious disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 35 | $151,574 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 18 | $93,772 |
| TivicayDolutegravir Sodium | 27 | $80,901 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 18 | $80,654 |
| PrezcobixDarunavir/Cobicistat | 20 | $47,247 |
| IsentressRaltegravir Potassium | 12 | $23,575 |
| Etravirine | 17 | $18,013 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 18 | $16,022 |
| Maraviroc | 11 | $14,546 |
| CeftriaxoneCeftriaxone Sodium | 23 | $466 |
| Abacavir-LamivudineAbacavir Sulfate/Lamivudine | 12 | $365 |
| Cephalexin | 21 | $297 |
| Penicillin V Potassium | 18 | $223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $32 | $232,22853 claims |
| Viiv Healthcare CompanyTriumeq, Tivicay | $29 | $174,67345 claims |
| Johnson & JohnsonPrezcobix | $28 | $47,24720 claims |
| MerckIsentress | $24,112 | $23,57512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 457 infectious disease providers in Pennsylvania.
Other infectious disease in Wynnewood
- David HornPhiladelphia$2.1M
- Judith WolfPhiladelphia$1.2M
- Karam MounzerPhiladelphia$712K
- William ShortPhiladelphia$520K
- David WuWest Chester$483K
- William PaceSouthampton$472K
- Amesh AdaljaPittsburgh$415K
- Timothy BabinchakPhoenixville$311K
- Tuesdae Stainbrookdu Bois$231K
- Micah JacobsPittsburgh$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.